$20.68
5.31%
Nasdaq, Fri, Dec 27 2024
ISIN
US87410C1045
Symbol
TALS
Sector
Industry

Talaris Therapeutics Inc Stock price

$20.68
-4.98 19.41% 1M
+7.45 56.31% 6M
-5.50 21.01% YTD
-7.68 27.08% 1Y
-44.13 68.09% 3Y
-54.83 72.61% 5Y
-54.83 72.61% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-1.16 5.31%
ISIN
US87410C1045
Symbol
TALS
Sector
Industry

Key metrics

Market capitalization $530.29m
Enterprise Value $248.66m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.65
Dividend yield 0.00%
Last dividend (FY23) $15.12
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-78.82m
Free Cash Flow (TTM) Free Cash Flow $-44.87m
Cash position $281.92m
EPS (TTM) EPS $-2.82
P/E forward negative
Short interest 1.28%
Show more

Is Talaris Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Talaris Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Talaris Therapeutics Inc forecast:

8x Buy
100%

Analyst Opinions

8 Analysts have issued a Talaris Therapeutics Inc forecast:

Buy
100%

Financial data from Talaris Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.03 0.03
98% 98%
-
- -
-
-
- Selling and Administrative Expenses 24 24
5% 5%
-
- Research and Development Expense 54 54
68% 68%
-
-80 -80
40% 40%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -79 -79
34% 34%
-
Net Profit -64 -64
2% 2%
-

In millions USD.

Don't miss a Thing! We will send you all news about Talaris Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Talaris Therapeutics, Inc. engages in cell therapy. It develops methods of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Its technologies are used to treat inherited metabolic enzyme disorders, red blood cell disorders to induce tolerance to organ transplants, and to treat autoimmune disorders such as type 1 diabetes, multiple sclerosis, rheumatoid arthritis, and scleroderma. The company was founded by Suzanne Ildstad in 2002 and is headquartered in Louisville, KY.

Head office United States
CEO Sandeep Kulkarni
Employees 52
Founded 2021
Website www.tourmalinebio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today